BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9251722)

  • 1. Peroxisome proliferator nafenopin potentiated cytotoxicity and genotoxicity of cyclophosphamide in the liver and bone marrow cells.
    Voskoboinik I; Drew R; Ahokas JT
    Chem Biol Interact; 1997 Jul; 105(2):81-97. PubMed ID: 9251722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effect of peroxisome proliferators on rat glutathione S-transferase isoenzymes.
    Voskoboinik I; Drew R; Ahokas JT
    Toxicol Lett; 1996 Oct; 87(2-3):147-55. PubMed ID: 8914623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The peroxisome proliferator class of non-genotoxic hepatocarcinogens synergize with epidermal growth factor to promote clonal expansion of initiated rat hepatocytes.
    James NH; Roberts RA
    Carcinogenesis; 1994 Dec; 15(12):2687-94. PubMed ID: 8001222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotoxic effects of selected peroxisome proliferators.
    Reisenbichler H; Eckl PM
    Mutat Res; 1993 Apr; 286(2):135-44. PubMed ID: 7681524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigations on the mechanism of liver tumour induction by peroxisome proliferators.
    Bentley P; Bieri F; Mitchell F; Waechter F; Stäubli W
    Arch Toxicol Suppl; 1987; 10():157-61. PubMed ID: 3495251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the hepatocarcinogen nafenopin, a peroxisome proliferator, on the activities of rat liver glutathione-requiring enzymes and catalase in comparison to the action of phenobarbital.
    Furukawa K; Numoto S; Furuya K; Furukawa NT; Williams GM
    Cancer Res; 1985 Oct; 45(10):5011-9. PubMed ID: 2862989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutathione S-transferase isoenzyme patterns in different subtypes of enzyme-altered rat liver foci treated with the peroxisome proliferator nafenopin or with phenobarbital.
    Grasl-Kraupp B; Waldhör T; Huber W; Schulte-Hermann R
    Carcinogenesis; 1993 Nov; 14(11):2407-12. PubMed ID: 8242872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferation and resistance to hydrogen peroxide in rat hepatocytes: is development of resistance an adaptation to cytotoxicity?
    Garberg P; Stenius U; Nilsson K; Högberg J
    Carcinogenesis; 1992 Oct; 13(10):1751-8. PubMed ID: 1423834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of acyl-CoA oxidase and cytochrome P450IVA1 RNA in rat primary hepatocyte culture by peroxisome proliferators.
    Bell DR; Elcombe CR
    Biochem J; 1991 Nov; 280 ( Pt 1)(Pt 1):249-53. PubMed ID: 1720616
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of primary cultures of adult rat hepatocytes to investigate mechanisms of action of nafenopin, a hepatocarcinogenic peroxisome proliferator.
    Bieri F; Bentley P; Waechter F; Stäubli W
    Carcinogenesis; 1984 Aug; 5(8):1033-9. PubMed ID: 6146407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative studies on nafenopin-induced hepatic peroxisome proliferation in the rat, Syrian hamster, guinea pig, and marmoset.
    Lake BG; Evans JG; Gray TJ; Körösi SA; North CJ
    Toxicol Appl Pharmacol; 1989 Jun; 99(1):148-60. PubMed ID: 2499080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone.
    Webb SJ; Xiao GH; Geoghegan TE; Prough RA
    Mol Pharmacol; 1996 Feb; 49(2):276-87. PubMed ID: 8632760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An overview of peroxisome proliferator-induced hepatocarcinogenesis.
    Rao MS; Reddy JK
    Environ Health Perspect; 1991 Jun; 93():205-9. PubMed ID: 1685443
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition instead of enhancement of lipid peroxidation by pretreatment with the carcinogenic peroxisome proliferator nafenopin in rat liver exposed to a high single dose of corn oil.
    Huber WW; Grasl-Kraupp B; Stekel H; Gschwentner C; Lang H; Schulte-Hermann R
    Arch Toxicol; 1997; 71(9):575-81. PubMed ID: 9285040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of peroxisome proliferation and liver growth-stimulating potential by nondirectly genotoxic compounds in cultured hepatocytes.
    Bieri F; Stäubli W; Kelly S; Waechter F; Bentley P
    Mol Toxicol; 1987-1988 Fall; 1(4):439-44. PubMed ID: 3151502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nafenopin, a peroxisome proliferator, depletes hepatic vitamin E content and elevates plasma oxidised glutathione levels in rats.
    Lake BG; Gray TJ; Körösi SA; Walters DG
    Toxicol Lett; 1989 Feb; 45(2-3):221-9. PubMed ID: 2919403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent peroxisome proliferators inhibit beta-oxidation in the isolated perfused rat liver.
    Bojes HK; Thurman RG
    Toxicol Appl Pharmacol; 1996 Oct; 140(2):322-7. PubMed ID: 8887448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of fatty acyl coenzyme A oxidase in the efflux of oxidized glutathione from perfused livers of rats treated with the peroxisome proliferator nafenopin.
    Conway JG; Neptun DA; Garvey LK; Popp JA
    Cancer Res; 1987 Sep; 47(18):4795-800. PubMed ID: 3621175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the effects of nafenopin on hepatic peroxisome proliferation and replicative DNA synthesis in the rat and Syrian hamster.
    Price RJ; Evans JG; Lake BG
    Food Chem Toxicol; 1992 Nov; 30(11):937-44. PubMed ID: 1473786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced expression of mature TGF beta 1 correlates with the suppression of rat hepatocyte apoptosis by the peroxisome proliferator, nafenopin.
    Strange J; Roberts RA
    Mutat Res; 1996 Nov; 372(1):107-13. PubMed ID: 9003537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.